Tactive Advisors LLC Invests $374,000 in AtriCure, Inc. $ATRC

Tactive Advisors LLC purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 13,367 shares of the medical device company’s stock, valued at approximately $374,000.

A number of other institutional investors have also recently modified their holdings of ATRC. Geneos Wealth Management Inc. purchased a new position in AtriCure in the second quarter worth $37,000. Smartleaf Asset Management LLC lifted its holdings in AtriCure by 59.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the period. Harbor Investment Advisory LLC purchased a new stake in shares of AtriCure during the 2nd quarter worth $40,000. Fifth Third Bancorp acquired a new position in shares of AtriCure during the 1st quarter worth $51,000. Finally, Global Retirement Partners LLC acquired a new position in shares of AtriCure during the 4th quarter worth $73,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure Stock Performance

NASDAQ:ATRC opened at $41.39 on Monday. The company has a market capitalization of $2.11 billion, a PE ratio of 197.10 and a beta of 1.20. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $43.18. The stock has a fifty day simple moving average of $32.25 and a 200-day simple moving average of $31.33.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same period in the prior year, the company earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts expect that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ATRC has been the subject of several recent analyst reports. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Wall Street Zen cut shares of AtriCure from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Citigroup reiterated a “market outperform” rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Raymond James Financial set a $52.00 price target on AtriCure in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $48.50.

Insider Buying and Selling

In related news, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the completion of the transaction, the insider directly owned 86,511 shares in the company, valued at $3,363,547.68. The trade was a 6.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Maggie Yuen sold 3,500 shares of AtriCure stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director owned 14,015 shares of the company’s stock, valued at $538,456.30. This represents a 19.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 47,246 shares of company stock valued at $1,777,845. 4.00% of the stock is owned by company insiders.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.